Astrazeneca plc's Farxiga (dapagliflozin), already the company's fifth best-selling product, now has a heart-failure component. The SGLT2 inhibitor met its phase III study's primary composite endpoint in reducing cardiovascular death or the worsening of heart failure compared to placebo in patients with reduced ejection fraction on standard-of-care treatment, including those with and without type 2 diabetes.